ABIVAX Société Anonyme (NASDAQ:ABVX) Short Interest Update

ABIVAX Société Anonyme (NASDAQ:ABVX) was the target of a large decrease in short interest in the month of October. As of October 31st, there was short interest totalling 191,900 shares, a decrease of 15.5% from the October 15th total of 227,200 shares. Based on an average daily trading volume, of 109,700 shares, the days-to-cover ratio is presently 1.7 days. Approximately 0.4% of the company’s stock are short sold.

Institutional Trading of ABIVAX Société Anonyme

A number of institutional investors have recently modified their holdings of ABVX. Janus Henderson Group PLC grew its stake in shares of ABIVAX Société Anonyme by 18.2% during the first quarter. Janus Henderson Group PLC now owns 851,839 shares of the company’s stock worth $12,113,000 after acquiring an additional 131,414 shares during the last quarter. BNP Paribas Financial Markets purchased a new stake in ABIVAX Société Anonyme during the 1st quarter worth approximately $81,000. abrdn plc increased its stake in ABIVAX Société Anonyme by 167.7% during the 3rd quarter. abrdn plc now owns 316,431 shares of the company’s stock valued at $3,645,000 after purchasing an additional 198,225 shares in the last quarter. Kennedy Capital Management LLC raised its holdings in shares of ABIVAX Société Anonyme by 35.3% in the first quarter. Kennedy Capital Management LLC now owns 120,168 shares of the company’s stock worth $1,718,000 after buying an additional 31,331 shares during the last quarter. Finally, Point72 Asset Management L.P. lifted its stake in shares of ABIVAX Société Anonyme by 28.2% during the third quarter. Point72 Asset Management L.P. now owns 542,900 shares of the company’s stock worth $6,254,000 after buying an additional 119,300 shares during the period. 47.91% of the stock is currently owned by institutional investors.

ABIVAX Société Anonyme Trading Down 4.6 %

ABVX opened at $9.50 on Friday. The business’s 50-day moving average is $10.58 and its two-hundred day moving average is $12.14. ABIVAX Société Anonyme has a 1 year low of $8.75 and a 1 year high of $17.02.

Analysts Set New Price Targets

Separately, Laidlaw initiated coverage on shares of ABIVAX Société Anonyme in a report on Monday, July 29th. They issued a “buy” rating and a $48.00 price target for the company. One equities research analyst has rated the stock with a hold rating and four have issued a buy rating to the company. According to data from MarketBeat.com, ABIVAX Société Anonyme currently has a consensus rating of “Moderate Buy” and an average price target of $39.80.

ABIVAX Société Anonyme Company Profile

ABIVAX Société Anonyme, a clinical-stage biotechnology company, focuses on developing therapeutics that harness the body's natural regulatory mechanisms to stablize the immune response in patients with chronic inflammatory diseases. The company is evaluating its lead drug candidate, obefazimod, in Phase 3 clinical trials for the treatment of moderately to severely active ulcerative colitis in adults.